We respond to trial showing blood test can quickly match targeted treatments to secondary breast cancer patients

Research presented by Professor Nicholas Turner at the San Antonio Breast Cancer Symposium suggests that a blood test could be used to match patients...

17 December 2019

We respond to study suggesting that ‘oestrogen only and oestrogen plus progestin have opposite effects on breast cancer incidence in post-menopausal women’

Research presented at the San Antonio Breast Cancer Symposium suggests that oestrogen only hormone replacement therapy, otherwise known as HRT, may...

17 December 2019

We respond to major trial showing the preventive effects of anastrozole continue for over five years after women stop taking it

Research presented at the San Antonio Breast Cancer Symposium has shown that the preventative effects of anastrozole, given to some women at high...

17 December 2019

We respond to study suggesting ‘partial breast irradiation may be as effective as whole breast irradiation in preventing recurrence in patients with early breast cancer’

Research presented at the San Antonio Breast Cancer Symposium suggests that partial breast radiotherapy could be as effective as whole breast...

16 December 2019

We respond to new imaging method which could help breast cancer patients avoid extensive surgery

  New ultrasound imaging method found to be as accurate as MRI in assessing the effectiveness of pre-surgery chemotherapy for breast...

4 December 2019

We respond to study suggesting that ‘permanent hair dye and chemical straighteners may increase breast cancer risk’

A new study by the National Institute of Health (US) suggests that using permanent hair dye and chemical straighteners could increase a woman’s...

4 December 2019

We respond to new estimations there are nearly three million people living with cancer in UK

Responding to new research released by Macmillan Cancer Support revealing there are nearly three million people living with cancer in the UK,...

29 November 2019

We respond to NICE approval of palbociclib with fulvestrant for use on the Cancer Drugs Fund

The National Institute for Health and Care Excellence (NICE) has today (28 November 2019) approved palbociclib in combination with hormone therapy...

28 November 2019

We respond to research investigating the possibility of using family history of breast cancer to adapt screening age

New research published in JAMA Oncology demonstrates how it may be possible to use family history of breast cancer to help adapt the starting age for...

21 November 2019